PRESSEFACH
WEITERE ADHOC-MELDUNGEN
Weng Fine Art beschließt Veräußerung von 50.000 eigenen Aktien
Veröffentlichung einer Kapitalmarktinformation
Alternative Gegenleistung zum freiwilligen Erwerbsangebot für Biofrontera-Aktien
Korrektur zur Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vertriebspartnerschaft mit SoftwareCentral
Ferax Capital AG veröffentlicht Halbjahreszahlen 2018
SHF Communication Technologies AG hebt Umsatz- und Ergebnisprognose für das Geschäftsjahr 2018 an
 
MELDUNG VOM 05.12.2017 16:30
Meldung drucken Artikel weiterleiten
pta20171205027
Public disclosure of inside information according to article 17 MAR
Pressefach Pressefach

Medigene AG: Medigene sells US-rights for Veregen® and raises financial guidance 2017

Planegg (pta027/05.12.2017/16:30) - Medigene AG (MDG1, Frankfurt, Prime Standard, TecDAX) today announced the sale of the US-rights for its drug Veregen® to Fougera Pharmaceuticals, Inc., Melville, New York, USA, the dermatology business entity of Sandoz US, which is part of the Novartis group. Thereby, Medigene essentially monetizes the last remaining product from its previous pipeline before the company's repositioning as an immunotherapy company with clinical programs in development.

Fougera, Medigene's former partner for the distribution and marketing of Veregen® in the US, now acquires the US assets for the drug, including intellectual property, licenses, know-how and the trademark. Medigene remains the owner of the active pharmaceutical ingredient (API) stock for the product and becomes the exclusive supplier of the API to Fougera. The parties agreed on certain minimum purchase obligations, in order to ensure the successful continuation of the US business by Fougera. Furthermore, Fougera will reimburse Medigene for costs associated with the supply of API. Medigene retains all rights for Veregen® outside of the US. Veregen® is a topical treatment of genital warts.

In the first nine months of 2017, Medigene's Veregen® revenue from royalties, product sales and milestone payments from its distribution partners totaled 1.8 m EUR (9M-2016: 2.2 m EUR). In the past, on average over 50% of the annual Veregen® revenue was generated from the US business.

In connection with the sale of the US-rights for Veregen®, Medigene raises its financial guidance for 2017: Now, the company expects revenues of EUR 10.5-11.5 m instead of EUR 8-10 m as previously guided, an EBITDA-loss of EUR 14-15 m instead of EUR 16-18 m, and a cash utilization of EUR 20-22 m instead of EUR 23-27 m. This forecast does not include future milestone payments from the existing R&D partnership with bluebird bio or any payments from potential new transactions.

Besides, financial details of the agreement with Fougera were not disclosed.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01
email: investor@medigene.com

(Ende)

Aussender: Medigene AG
Lochhamer Straße 11
82152 Planegg
Deutschland
Ansprechpartner: Julia Hofmann, Head of Public and Investor Relations
Tel.: +49 89 200033-3301
E-Mail:
Website: www.medigene.de
ISIN(s): DE000A1X3W00 (share)
Börsen: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
Medigene AG
AKTUELLE BUSINESS NEWS
20.07.2018 17:30
Filterhersteller Dexwet drängt an die NASDAQ
Dexwet International AG
20.07.2018 13:47
Deutsche Start-ups verzichten auf Geld vom Staat
pressetext.redaktion
20.07.2018 10:00
D.A.S.: Zehntes Mal in Folge mit A-Rating
D.A.S. Rechtsschutz AG
20.07.2018 06:10
"Atmosphärische Führung" steigert Produktivität
pressetext.redaktion
19.07.2018 11:30
Griechenlands Privatwirtschaft hat kaum Potenzial
pressetext.redaktion
Weitere News anzeigen